165 related articles for article (PubMed ID: 22564245)
41. p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines.
Ye S; Shen J; Choy E; Yang C; Mankin H; Hornicek F; Duan Z
Cancer Chemother Pharmacol; 2016 Feb; 77(2):349-56. PubMed ID: 26698867
[TBL] [Abstract][Full Text] [Related]
42. Murine double minute 2 siRNA and wild-type p53 gene therapy enhances sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro and in vivo.
Gu J; Tang Y; Liu Y; Guo H; Wang Y; Cai L; Li Y; Wang B
Cancer Lett; 2014 Feb; 343(2):200-9. PubMed ID: 24161623
[TBL] [Abstract][Full Text] [Related]
43. Targeting autophagy augments the activity of DHA-E3 to overcome p-gp mediated multi-drug resistance.
Xi G; Wang M; Sun B; Shaikh AS; Liu Y; Wang W; Lou H; Yuan H
Biomed Pharmacother; 2016 Dec; 84():1610-1616. PubMed ID: 27825801
[TBL] [Abstract][Full Text] [Related]
44. Nobiletin (NOB) suppresses autophagic degradation via over-expressing AKT pathway and enhances apoptosis in multidrug-resistant SKOV3/TAX ovarian cancer cells.
Jiang YP; Guo H; Wang XB
Biomed Pharmacother; 2018 Jul; 103():29-37. PubMed ID: 29635125
[TBL] [Abstract][Full Text] [Related]
45. Interfering EZH2 Expression Reverses the Cisplatin Resistance in Human Ovarian Cancer by Inhibiting Autophagy.
Sun Y; Jin L; Liu JH; Sui YX; Han LL; Shen XL
Cancer Biother Radiopharm; 2016 Sep; 31(7):246-52. PubMed ID: 27610467
[TBL] [Abstract][Full Text] [Related]
46. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression.
Zhan M; Yu D; Lang A; Li L; Pollock RE
Cancer; 2001 Sep; 92(6):1556-66. PubMed ID: 11745235
[TBL] [Abstract][Full Text] [Related]
47. Molecular cytogenetic analysis of chemoresistant non-Hodgkin's lymphoma patients with p53 abnormalities using fluorescence in situ hybridisation and comparative genomic hybridisation.
Foroutan B; Zitzelsberger H; Bauer V; Ruf AA; Baumgartner A; Anderson D
Arch Iran Med; 2011 Sep; 14(5):321-6. PubMed ID: 21888455
[TBL] [Abstract][Full Text] [Related]
48. [Mdr-1 ribozyme in the reversal of multidrug resistance in human ovarian cancer].
Yang XK; Xing H; Gao QL; Wang W; Wu SF; Lu YP; Wang SX; Ma D
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):425-8. PubMed ID: 14575561
[TBL] [Abstract][Full Text] [Related]
49. Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer.
Zahedi P; De Souza R; Huynh L; Piquette-Miller M; Allen C
Mol Pharm; 2011 Feb; 8(1):260-9. PubMed ID: 21166459
[TBL] [Abstract][Full Text] [Related]
50. Nanomaterial-induced autophagy: a new reversal MDR tool in cancer therapy?
Panzarini E; Dini L
Mol Pharm; 2014 Aug; 11(8):2527-38. PubMed ID: 24921216
[TBL] [Abstract][Full Text] [Related]
51. Autophagy takes place in mutated p53 neuroblastoma cells in response to hypoxia mimetic CoCl(2).
Naves T; Jawhari S; Jauberteau MO; Ratinaud MH; Verdier M
Biochem Pharmacol; 2013 Apr; 85(8):1153-61. PubMed ID: 23380477
[TBL] [Abstract][Full Text] [Related]
52. Autophagy induction by low-dose cisplatin: the role of p53 in autophagy.
Cho KH; Park JH; Kwon KB; Lee YR; So HS; Lee KK; Lee SY; Moon SR; Yang SH
Oncol Rep; 2014 Jan; 31(1):248-54. PubMed ID: 24173208
[TBL] [Abstract][Full Text] [Related]
53. Icariin inhibits autophagy and promotes apoptosis in SKVCR cells through mTOR signal pathway.
Jiang S; Chang H; Deng S; Fan D
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):4-10. PubMed ID: 29808793
[TBL] [Abstract][Full Text] [Related]
54. Autophagic flux promotes cisplatin resistance in human ovarian carcinoma cells through ATP-mediated lysosomal function.
Ma L; Xu Y; Su J; Yu H; Kang J; Li H; Li X; Xie Q; Yu C; Sun L; Li Y
Int J Oncol; 2015 Nov; 47(5):1890-900. PubMed ID: 26397057
[TBL] [Abstract][Full Text] [Related]
55. Andrographolide radiosensitizes human ovarian cancer SKOV3 xenografts due to an enhanced apoptosis and autophagy.
Zhang C; Qiu X
Tumour Biol; 2015 Nov; 36(11):8359-65. PubMed ID: 26014516
[TBL] [Abstract][Full Text] [Related]
56. A novel manganese complex, Mn-(II) N-(2-hydroxy acetophenone) glycinate overcomes multidrug-resistance in cancer.
Ghosh RD; Banerjee K; Das S; Ganguly A; Chakraborty P; Sarkar A; Chatterjee M; Choudhuri SK
Eur J Pharm Sci; 2013 Jul; 49(4):737-47. PubMed ID: 23665413
[TBL] [Abstract][Full Text] [Related]
57. Characterization of an etoposide-resistant human ovarian cancer cell line.
Kubota N; Nishio K; Takeda Y; Ohmori T; Funayama Y; Ogasawara H; Ohira T; Kunikane H; Terashima Y; Saijo N
Cancer Chemother Pharmacol; 1994; 34(3):183-90. PubMed ID: 7911742
[TBL] [Abstract][Full Text] [Related]
58. Characterization of salvicine-resistant lung adenocarcinoma A549/SAL cell line.
Miao ZH; Tong LJ; Zhang JS; Han JX; Ding J
Int J Cancer; 2004 Jul; 110(5):627-32. PubMed ID: 15146550
[TBL] [Abstract][Full Text] [Related]
59. Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer.
Ren F; Shen J; Shi H; Hornicek FJ; Kan Q; Duan Z
Biochim Biophys Acta; 2016 Dec; 1866(2):266-275. PubMed ID: 27717733
[TBL] [Abstract][Full Text] [Related]
60. Andrographolide promotes vincristine-induced SK-NEP-1 tumor cell death via PI3K-AKT-p53 signaling pathway.
Zhang M; Xue E; Shao W
Drug Des Devel Ther; 2016; 10():3143-3152. PubMed ID: 27729773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
